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Introduction
Adoptive T cell therapy is clinically effective in some tumor settings (1, 2). However extending this approach 
to other cancers is limited by a paucity of  defined tumor-specific antigens that can be safely targeted and, 
particularly for solid tumors, the inability of  effector lymphocytes to access the malignant cells and/or func-
tion within the immunosuppressive tumor microenvironment. Therefore, rather than target the malignant 
cells directly, an alternative approach is to target the tumor vasculature upon which the cancer depends.
Endothelial cells that line the vasculature within tumors are subject to a different extracellular envi-
ronment compared with endothelial cells in healthy tissue. For example, in tumors, they may be exposed 
to hypoxia, nutrient deprivation, more acidic conditions, and different mechanical forces such as reduced 
blood flow rate and increased mechanical compression (3). Accordingly, the tumor vasculature displays 
a different transcriptome compared with healthy tissues, with expression of  tumor endothelial markers 
(TEMs) that could be targeted therapeutically.
Targeting the tumor vasculature offers several advantages over targeting malignant cells directly. 
First, endothelial cells are in direct contact with the circulation and therefore easily accessible to agents 
delivered i.v. Second, it is not necessary to kill the endothelial cells, since even temporary changes in 
their shape or function could lead to a blood clot and thereby destruction of  surrounding tumor tissue. 
Third, shutting down 1 vessel will affect not only tumor cells in the immediate vicinity but also all tumor 
tissue downstream of  this blood supply. Fourth, some TEMs are broadly expressed on the vasculature of  
different tumor types. Fifth, tumor vascular endothelial cells are more genetically stable than malignant 
cells (4) and, thus, less likely to generate antigen-loss immune escape variants.
Engineering T cells to express chimeric antigen receptors (CARs) specific for antigens on 
hematological cancers has yielded remarkable clinical responses, but with solid tumors, benefit 
has been more limited. This may reflect lack of suitable target antigens, immune evasion 
mechanisms in malignant cells, and/or lack of T cell infiltration into tumors. An alternative 
approach, to circumvent these problems, is targeting the tumor vasculature rather than the 
malignant cells directly. CLEC14A is a glycoprotein selectively overexpressed on the vasculature of 
many solid human cancers and is, therefore, of considerable interest as a target antigen. Here, we 
generated CARs from 2 CLEC14A-specific antibodies and expressed them in T cells. In vitro studies 
demonstrated that, when exposed to their target antigen, these engineered T cells proliferate, 
release IFN-γ, and mediate cytotoxicity. Infusing CAR engineered T cells into healthy mice showed 
no signs of toxicity, yet these T cells targeted tumor tissue and significantly inhibited tumor growth 
in 3 mouse models of cancer (Rip-Tag2, mPDAC, and Lewis lung carcinoma). Reduced tumor burden 
also correlated with significant loss of CLEC14A expression and reduced vascular density within 
malignant tissues. These data suggest the tumor vasculature can be safely and effectively targeted 
with CLEC14A-specific CAR T cells, offering a potent and widely applicable therapy for cancer.
2insight.jci.org   https://doi.org/10.1172/jci.insight.138808
R E S E A R C H  A R T I C L E
The potency of  T cell–based therapies for cancer probably reflects the cytotoxic nature of  T-lympho-
cytes, as well as their ability to self-replicate and recruit other components of  the cellular immune response. 
However, naturally occurring T cells specific for tumor antigens are often of  low avidity due to immunolog-
ical self-tolerance. Nevertheless, T cells can be genetically engineered to express high-affinity conventional 
or chimeric T cell receptors (5, 6). T cells engineered to express a chimeric antigen receptor (CAR) targeting 
CD19 have mediated remarkable clinical responses in leukemia and lymphoma patients (7). CARs usu-
ally comprise a monoclonal antibody–derived single-chain variable fragment (scFv; consisting of  a heavy 
and light chain joined by a flexible linker) fused through a transmembrane domain to the cytoplasmic 
CD3ζ chain. More recently, constructs have incorporated additional cytoplasmic signaling domains from 
costimulatory molecules such as CD28 or 4-1BB to enhance CAR T cell survival in vivo (8). CARs there-
fore combine the specificity and affinity of  a tumor-specific antibody with the potent effector functions 
of  self-replicating T cells. Importantly, since CARs recognize native cell surface antigens independent of  
antigen processing, they are neither MHC restricted nor dependent on the antigen processing capacity of  
target cells. Therefore, they can be applied to all patients, regardless of  HLA type, and recognize tumors 
with downregulated HLA expression.
Currently, most CAR therapy approaches are targeting antigens expressed by the malignant cells, 
but some are targeting TEMs such as vascular endothelial cell growth factor receptor 1 (VEGFR1) and 
VEGFR2 (9–11), prostate-specific membrane antigen (PSMA) (12), αvβ3 integrin (13), TEM8 (14), or 
EIIIB, a splice variant of  fibronectin (15). In all cases, T cells expressing CARs specific for the TEM 
mediated significant inhibition of  tumor growth in mouse models, although mouse studies have also 
reported toxicity when targeting some of  these markers (9, 16). To date, only a VEGFR2-specific CAR 
has been tested clinically; out of  24 patients treated, 1 patient had a partial response, but others were unre-
sponsive (NCT01218867, https://clinicaltrials.gov/ct2/show/results/NCT01218867). Clinical trials of  
PSMA-specific CARs are ongoing.
Previously, we identified the glycoprotein CLEC14A as a TEM, highly expressed on the surface of  
vascular endothelial cells in many common human cancers but expressed at low or undetectable levels in 
healthy tissue (17). More recently, we have conducted an extensive analysis of  CLEC14A protein and gene 
expression in healthy and diseased human and primate tissues, and we confirmed this protein to be a highly 
promising target, especially in renal cell cancer (18). CLEC14A expression can be induced under condi-
tions of  low shear stresses (17), such as occur in ill-formed vessels of  tumor tissue, but other mechanisms 
may also contribute, including activin receptor–like kinase 1 signaling (19) and hypoxia (20). CLEC14A 
is a member of  the type 14 family of  calcium-dependent C-type lectins that includes endosialin/TEM1/
CD248, thrombomodulin, and CD93 (21). This single-pass type I transmembrane protein (499 amino acids 
[aa] long) contains one C-type lectin–like domain (aa 33–173) and an epidermal growth factor–like domain 
(aa 245–287) in the extracellular region (UniProt). Human and mouse CLEC14A proteins show 67% aa 
sequence identity, with 78% and 79% identity within the C-type lectin and epidermal growth factor-like 
domains, respectively. It interacts with multimerin-2 within the extracellular matrix (22) and regulates 
VEGFR2- and VEGFR3-dependent signalling (23). CLEC14A mediates filipodia formation and endothe-
lial migration (17, 24), plays a role in sprouting angiogenesis, and promotes tumor growth in mice (22).
In the present study, we explored targeting tumor vasculature using CLEC14A-specific CAR-express-
ing T cells. Having characterized the function of  these cells in vitro, we then explored their efficacy and 
preliminary safety using 3 mouse tumor models.
Results
Generation and expression of  CLEC14A-specific CARs. Monoclonal antibodies to CLEC14A that cross-re-
act with human and mouse forms of  the protein were previously generated by vaccinating mice with 
the extracellular domain of  mouse CLEC14A. To confirm the specificity of  2 of  these antibodies 
(CRT3 and CRT5), they were used to stain HUVECs following siRNA knockdown of  human CLE-
C14A protein (note CLEC14A is naturally expressed in HUVECs under static culture conditions; ref. 
17). Using flow cytometry, clear staining was detected on HUVECs treated with a noncomplementary 
siRNA duplex control, whereas staining of  HUVECs treated with siRNA targeting CLEC14A was 
reduced to almost background levels (Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.138808DS1). Using reverse transcription PCR 
(RT-PCR) and degenerate primer sets, a gene construct encoding an scFv was then generated for each 
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of  these antibodies and cloned into a retroviral vector to encode a second-generation CAR in which 
the scFv was linked to the human CD28 costimulatory domain and human CD3ζ chain (Figure 1A). 
In all constructs, the CAR gene was separated from a truncated human CD34 marker gene by a foot-
and-mouth disease virus 2A peptide linker ensuring equimolar expression of  both genes. In this way, 
CD34 expression acted as a marker for CAR expression.
Human T cells were then transduced with these retroviral constructs and analyzed by flow cytometry. 
As illustrated in Figure 1B, CD34 expression was readily detected in T cells transduced with vectors encod-
ing CARs based on either of  the 2 CLEC14A-specific antibodies. Using recombinant CLEC14A protein, it 
was also possible to stain directly for surface CAR expression (Figure 1C).
In vitro functions of  CLEC14A-specific CAR engineered T cells. In vitro tests were used to assess the 
function of  these engineered T cells. Using an ELISA to detect IFN-γ release, T cells expressing the 
CARs were diluted with mock T cells to equalize the proportion of  transduced cells, and they were then 
compared for their ability to respond to human CLEC14A. The target antigen was expressed either as 
a recombinant Fc-fusion protein immobilized on a plate, overexpressed on the surface of  engineered 
CHO cells, or naturally expressed at physiological levels on the surface of  HUVECs grown under static 
culture conditions. As shown in Figure 1, D–F, in all cases, there was a specific response to CLEC14A 
above control targets. Note that these CAR T cells also produced the cytokines TNF-α and IL-2 in 
response to CLEC14A (Supplemental Figure 2).
Using a chromium release assay, we assessed the cytotoxic function of  the CAR T cells. CHO cells 
expressing human CLEC14A (or CHO cells plus vector only control) were cocultured with CAR T cells or 
mock T cells. Again CAR T cell preparations were diluted with mock T cells to equalize for transduction 
efficiencies. Both CAR constructs tested mediated specific lysis of  CLEC14A+ targets (Figure 2A).
CFSE labeling of  CAR T cells demonstrated that they can also proliferate when cultured with 
HUVECs. This proliferation was induced only in CD34+ T cells and not in the nontransduced (CD34–) 
subset within the T cell preparation, indicating that it is in response to CLEC14A (Figure 2B).
Next, we sought to compare responses of  our CAR T cells with human and mouse versions of  CLEC14A. 
CAR T cell preparations were diluted with mock T cells to equalize for transduction efficiencies and cultured 
in wells precoated with recombinant CLEC14A-Fc fusion proteins (or Fc alone). Results shown in Figure 2C 
demonstrate that T cells expressing either CAR3.28z or CAR5.28z responded to mouse CLEC14A, albeit to 
a lesser degree than their response to human CLEC14A. Given this response to mouse CLEC14A, further 
studies on safety and antitumor effects were possible in vivo using mouse models.
Expression profile of  CLEC14A in mouse organs. In preparation for in vivo studies, we first needed to 
determine the expression of  CLEC14A in healthy mouse tissues to see if  it mirrored that seen in human 
tissues. Therefore, we performed immunofluorescence staining for CLEC14A on frozen tissue sections 
from multiple organs collected from 3 healthy WT female adult C57BL/6J mice. Results demonstrated 
that expression does indeed mirror that seen in human tissue, with little or no CLEC14A detectable in adult 
mouse tissues. As in humans (data not shown), CLEC14A was detected in the placenta, a site of  active 
angiogenesis, and this colocalized with the vasculature (Figure 3).
Safety testing of  CAR T cells in healthy mice. Having shown that the mouse is an appropriate model for 
safety testing, C57BL/6J mice were conditioned with 4 Gy total body irradiation (TBI) to aid T cell engraft-
ment and subsequently infused i.v. with 20 million T cells/mouse (where 20% of  T cells expressed either 
CAR3.28z or CAR5.28z). As a control, other mice received 20 million mock-transduced T cells. Infused 
T cells were generated from a congenic (CD45.1) mouse strain and were, thus, distinguishable from host 
T cells. Mice were monitored carefully for toxicity over the next 6 weeks, and using serial blood samples, 
infused CAR T cells were tracked by CD34 and CD45.1 staining.
As shown in Figure 4A, the infused (CD45.1+) T cells were detectable throughout this period, initially 
representing the majority of  T cells within the circulation of  the mice. Their relative abundance gradually 
decreased with time, probably due to cell death and/or recovery of  the host’s endogenous (CD45.1–) T 
cell population after conditioning. Nevertheless, the proportion of  infused T cells that expressed the CARs 
(CD34+) remained relatively consistent throughout this period (Figure 4B), suggesting that the infused T 
cells were not responding to target antigen in healthy tissues. Despite the presence of  CAR T cells, the mice 
showed no ill effects, as illustrated by a consistent gain in body weight in both CAR- and mock-treated animals 
(Figure 4C). On day 45, mice were sacrificed, and vital organs were collected and H&E stained for analysis 
by an experienced mouse histopathologist; no signs of  pathology were observed (Supplemental Figure 3). 
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Figure 1. CLEC14A-specific CAR design, expression, and function. (A) Schematic representation of a recombinant 
retroviral vector encoding CLEC14A-specific CARs. Retroviral CAR vector (pMP71) coexpresses a truncated CD34 
marker gene and an scFv fragment/CD3ζ chain chimeric receptor with a CD28 costimulatory domain. Expression 
is driven from the LTR promoter, and the 2A peptide linker ensures equimolar expression of both molecules. (B) 
Recombinant retroviral expression vectors encoding CARs CAR3.28z and CAR5.28z (with scFv fragments from 
CLEC14A-specific monoclonal antibodies CRT3 or CRT5, respectively) were used to transduce human T cells. CAR 
expression was detected by staining for the CD34 marker. Percentage values show proportion of cells stained for 
CD34 compared with mock-transduced T cells. (C) Transduced T cells stained for expression of CAR using CLE-
C14A-Fc (percentage values show specific binding of CLEC14A-Fc having subtracted background staining with Fc 
alone). (D–F) Human T cells engineered to express putative CLEC14A-specific CARs (or mock-transduced T cell 
controls) were tested using an ELISA for IFN-γ production for response to plate-bound recombinant CLEC14A-Fc 
(extracellular domain) fusion protein (or Fc alone) (D), CHO cells engineered to express full-length human CLEC14A 
(or CHO transduced with vector alone) (responder/stimulator [R/S] ratio = 6:1) (E), and HUVECs naturally expressing 
CLEC14A (or medium alone). (R/S ratio = 1:1) (F). In all cases, the different CAR T cell lines were diluted with mock  
T cells to equalize for transduction efficiency. Cells were stimulated for 18 hours before testing for IFN-γ produc-
tion. Results of ELISAs show data from 6–7 repeat experiments, having subtracted background responses of T cells 
alone. All P values shown were calculated using a Wilcoxon matched-pairs signed rank test.
5insight.jci.org   https://doi.org/10.1172/jci.insight.138808
R E S E A R C H  A R T I C L E
Importantly, at the end of  the experiment, ex vivo analysis of  CD34+ CAR T cells sorted from the spleens 
of  these animals demonstrated that the CAR T cells had retained functional activity, producing IFN-γ in 
response to both human and mouse recombinant CLEC14A proteins (Figure 4D). When 10 million T cells 
expressing a CLEC14A-specific CAR were injected into a knockin mouse expressing the human rather than 
mouse CLEC14A extracellular domain, we again observed no toxicity (Supplemental Figure 4). The CAR 
T cells did not affect wound healing in WT mice (Figure 5).
Antitumor responses with CLEC14A-specific CAR engineered T cells. To determine the ability of  the engi-
neered T cells to inhibit tumor growth, we used 3 mouse tumor models. In vitro studies had shown little 
difference between CAR3.28z and CAR5.28z, so we began analyzing antitumor effects in vivo by focusing 
on CAR5.28z-expressing T cells. T cells from C57BL/6J mice were engineered to express CAR5.28z (or 
mock-transduced) and injected i.v. into 12-week-old Rip-Tag2 mice. These mice develop hyperplastic islets 
at 3–4 weeks of  age, and by 10 weeks, small encapsulated adenomas emerge. By 12–13 weeks, these adeno-
mas become much larger, and death normally occurs at approximately 14 weeks.
Figure 2. Further characterization of functional 
responses in CAR-transduced T cells. (A) Human 
T cells expressing CLEC14A-specific CARs (or mock 
T cell controls) were tested for cytotoxicity against 
CHO cells engineered to express full-length human 
CLEC14A (or control CHO cells transduced with vector 
alone). Results show data from 8 repeat experiments 
(effector/target ratio = 9:1). (B) Such T cells were also 
tested for proliferation, measured by CFSE staining 
of CD34+ T cells (solid line) and CD34– T cells (dotted 
line) when cocultured with HUVECs or medium alone 
(unstimulated). Results show a histogram of T cells 
expressing CAR5.28z, and the 2 graphs below show 
data from 2 repeat experiments giving the percent-
age of CD34+ cells that proliferated for each of the 
CARs indicated (having subtracted the percentage of 
CD34+ T cells that proliferated in medium alone). (C) 
CLEC14A-specific CAR T cells (or mock T cell controls) 
were also tested for IFN-γ release in response to 
plate-bound recombinant human or mouse CLEC14A 
(both expressed as Fc-fusion proteins) or to Fc alone. 
Results show data from 6 repeat experiments. All 
P values shown were calculated using a Wilcoxon 
matched-pairs signed rank test.
6insight.jci.org   https://doi.org/10.1172/jci.insight.138808
R E S E A R C H  A R T I C L E
To perform a regression trial, CAR-treated Rip-Tag2 mice (n = 12 per group) received a total of  15 
million cells, of  which 2.4 million expressed CAR5.28z. As a control, another 12 Rip-Tag2 mice were 
injected with 15 million T cells that lacked the CAR (i.e., mock-transduced). To aid T cell engraftment, 
all animals were irradiated (4 Gy) 24 hours before T cell infusion. As previously described (25–27), all 
mock-treated animals were culled at 14 weeks of  age due to tumor growth, and pancreatic dysfunction 
and tumor size was measured. CAR-treated animals were analyzed at 16 weeks of  age, allowing for the 
standard 4-week time period of  treatment used for the regression trial (25).
As shown in Figure 6A, tumor size in CAR-treated mice was significantly reduced compared with 
mock-treated animals, even though CAR-treated tumors were allowed to grow for a further 2 weeks. 
Four of  12 mock-treated animals died before 14 weeks of  age and were excluded from the analysis of  
tumor size. In contrast, all 12 CAR-treated animals survived to 14 weeks, and remarkably, all but 2 
survived to 16 weeks of  age. These data suggest that CAR T cell treatment is able to regress pancre-
atic tumor and, at the same time, prolong the survival of  Rip-Tag2 mice. Of  note, the mean tumor 
size in mock-treated animals was lower than in untreated (nonirradiated) mice, implying irradiation of  
mock-treated animals may have partially affected tumor growth, although this difference was not signif-
icant (P = 0.15, Mann-Whitney U test). Staining for the CD34 marker in tumor tissue recovered from 
Figure 3. Immunofluorescence staining for CLEC14A in healthy mouse tissues. Confocal images of CLEC14A immuno-
fluorescence staining of healthy mouse tissue. Green, MECA32 (kidney) or CD31 (all other tissues) staining for endothe-
lial cells. Red, CLEC14A staining. Scale bars: 100 μm.
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Figure 4. Toxicity testing of mouse 
T cells expressing CLEC14A-specific 
CARs in healthy mice. C57BL/6 mice 
were conditioned by irradiation and 
then infused with mouse T cells from a 
congenic (CD45.1+) strain. These T cells 
expressed CAR3.28z (n = 5), CAR5.28z 
(n = 5), or no CAR (mock; n = 2). (A and 
B) Serial blood samples were analyzed 
by flow cytometry to determine the 
percentage of infused T cells in the 
circulating T cell pool (A) and the 
percentage of CAR-expressing (CD34+) 
T cells in the infused T cell population 
(B). (C) The animals showed no signs of 
toxicity, as illustrated by their consis-
tent increase in body weight. Results 
in A–C show the mean ± SEM. (D) Ex 
vivo analysis of CAR-expressing T cells 
(or mock T cells) recovered from the 
spleens of animals at the end of the 
experiment tested by ELISA for their 
ability to release IFN-γ when exposed 
to recombinant human or mouse 
CLEC14A protein. Results in D show the 
mean of triplicate cultures (±SD), with 
P values calculated using an unpaired t 
test, and are representative of 2 repeat 
experiments. All t tests were 2 tailed.
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mice at the end of  this experiment demonstrated that CAR-expressing T cells were present at the tumor 
site (Figure 6B). There was also a statistically significant decrease in both the total number of  vessels 
and the proportion of  CLEC14A-expressing vessels within tumors of  CAR-treated mice compared with 
the mock-treated controls (Figure 6, C and D). Cleaved caspase-3 expression in these tumors indicated 
that CAR treatment was inducing apoptosis in the tumor vasculature (Figure 6E).
A second pancreatic tumor model, murine pancreatic ductal adenocarcinoma (mPDAC), also express-
es high levels of  CLEC14A in the tumor vasculature (Figure 7A). PDAC tumor cells were injected into 
the pancreas of  FVB/n mice, and 1 week later, mice were conditioned using cyclophosphamide to aid T 
cell engraftment. The following day, CAR5.28z- or mock-transduced syngeneic T cells were injected into 
the tail vein, and tumor size was measured 3 weeks later. As shown in Figure 7B, there was a significant 
inhibition of  tumor growth in CAR-treated mice, and histological examination of  tumor tissue demon-
strated that there was also a significant reduction in the vasculature of  CAR-treated tumors, with loss of  
CLEC14A-expressing vessels (Figure 7, C–E).
Further studies explored the antitumor effects of  CAR5.28z using the syngeneic LLC mouse model. 
Here, we tested CAR3.28z to determine if  this other construct was also capable of  inhibiting tumor 
growth. When injected s.c. on the flank of  a C57BL/6J mouse, LLC cells grow rapidly, forming large 
tumors within 3–4 weeks. Previous studies have demonstrated that CLEC14A is upregulated on vessels 
in this tumor and promotes tumor growth (22). Staining LLC for CLEC14A protein confirmed expres-
sion on some vessels within these tumors (Figure 8A). Four days after tumor inoculation, mice were 
injected i.v. with syngeneic T cells expressing either CAR3.28z or CAR5.28z (or mock transduced). 
Over the next 18 days, there was a statistically significant inhibition of  tumor growth in CAR-treated 
mice compared with mice treated with mock-transduced T cells. This was apparent from biolumines-
cent imaging of  the luciferase-expressing tumor cells, caliper measurements of  the same tumors, and 
tumor mass at the end of  the experiment (Figure 8, B–D).
Importantly, no CAR T cell–mediated toxicity was apparent in any of  these tumor mouse models, 
supporting the data obtained in our studies with healthy mice.
Figure 5. CLEC14A-specific CAR T cells do not affect wound healing. C57BL/6 mice were injected s.c. on the flank with 
1 × 106 LLC cells and, 4 days later, injected with CLEC14A-specific CAR T cells (n = 7) or mock-transduced cells (n = 7). 
The next day, skin wounds were administered to the opposite flank of the mouse. (A) The size of the wound area was 
recorded over time (n = 7 mice per group; data shown are mean ± SEM). (B) Representative images of the wounds from 
mock- and CAR-treated mice at the time points indicated.
9insight.jci.org   https://doi.org/10.1172/jci.insight.138808
R E S E A R C H  A R T I C L E
Figure 6. Antitumor responses in Rip-Tag2 mice. Rip-Tag2 mice at 12 weeks of age were conditioned with 4 Gy total body irradiation and then infused with 
CAR5.28z-expressing mouse T cells (n = 12) or mock-transduced mouse T cells (n = 12). (A) Tumor size was measured at 14 or 16 weeks of age for mock- and 
CAR-treated animals, respectively. Results show tumor size for individual mice that survived to the end of the experiment, along with the mean ± SEM. 
Tumor sizes in 12 untreated (nonirradiated) mice measured at 14 weeks of age are included as a control. (B) CAR-transduced (CD34+) T cells were detectable 
by immunofluorescent imaging in CAR-treated RIP-Tag2 tumors 4 weeks after injection (red, CD34; green, MECA32 endothelial marker; blue, DAPI stain). 
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Discussion
Tumor vasculature not only supplies oxygen and nutrients to aid tumor growth, but it can also provide 
factors that maintain self-renewing cancer stem cells (28) and release growth signals that promote malig-
nant cell proliferation (29). Furthermore, tumor endothelium may contribute to immune escape through 
expression of  receptors that inhibit T cell activation (e.g., PD-L1, PD-L2) (30) and FasL expression, which 
preferentially kills CD8+ T cells but not Tregs (31). Furthermore, activated endothelin B receptor on tumor 
endothelium can inhibit T cell recruitment (32), whereas upregulation of  common lymphatic and vascu-
lature endothelial receptor-1 (CLEVER1) may selectively enhance Treg recruitment (33). Consequently, 
tumor vasculature plays an important role in tumor growth and survival, and so targeting it for destruction 
should significantly impact disease.
Therefore, the present study explored the efficacy and preliminary safety of  targeting a TEM CLE-
C14A. CLEC14A plays a role in angiogenesis (17, 22), so targeting it should not only eliminate exist-
ing tumor vasculature, but it should also inhibit formation of  new blood vessels in tumor tissue. Previ-
ous work with a CLEC14A-specific antibody demonstrated antiangiogenic and antitumor effects in the 
LLC mouse model by blocking the interaction between CLEC14A and multimerin-2 (22). However, 
given the potent cytotoxic and immunoregulatory activity of  self-replicating T cells, we reasoned that 
CARs could be more effective than blocking antibodies, since they act as vascular disrupting agents 
with cytotoxic rather than cytostatic functions. Our CLEC14A-specific CAR T cells were capable of  
IFN-γ release, cytotoxicity, and proliferation in response to their target antigen, indicating their antitu-
mor potential. We incorporated the CD28 costimulatory domain into our CAR constructs, as previous 
studies have demonstrated that this enhances the function of  these cells (8). Alternative or additional 
costimulatory domains (e.g., from 4-1BB) may further enhance the antitumor efficacy of  CAR T cells 
by increasing their persistence and altering their metabolic profile (34).
Encouragingly, when injected into healthy mice, we demonstrated persistence of  functional CLE-
C14A-specific CAR T cells without toxicity. This is consistent with our findings that CLEC14A is absent 
or expressed at low levels in healthy mouse tissues. Importantly, the same expression pattern is found in 
humans (17, 18). In vitro, our CAR T cells responded more strongly to human CLEC14A than the equiv-
alent mouse protein (Figure 2C and Figure 4D). Therefore, we also tested for toxicity using healthy mice 
expressing the human CLEC14A extracellular domain, but again, no toxicity was observed. There was 
also no effect on wound healing rates in tumor-bearing WT mice. Not only did the CAR T cells appear 
safe, but following a single injection, they mediated significant inhibition of  tumor growth in 3 different 
tumor models, including spontaneous and orthotopic tumors and 2 different mouse strains, with evidence 
of  T cell targeting and destruction of  the CLEC14A-expressing tumor vasculature. Before clinical studies 
can commence, further testing of  the CARs when expressed in human T cells is required, but these results 
strongly support the therapeutic potential of  this approach.
Although the CLEC14A-specific CARs inhibited tumor growth, some tumor tissue remained, support-
ed by a reduced vasculature that largely did not express the target antigen (Figure 6, C and D). Therefore, to 
improve the efficacy of  CLEC14A-specific CAR-based therapy for solid tumor vasculature, future studies 
could explore combining this approach with CARs targeting other TEMs to increase the proportion of  
tumor vessels that can be targeted. It may also be possible to further engineer the CAR T cells to improve 
their function in a hostile immunosuppressive tumor microenvironment. For example, coexpression of  
cytokines IL-12 (35) or IL-15 (10) by other CAR T cells targeting the vasculature increased their antitumor 
efficacy. Engineering expression of  dominant-negative receptors may also assist in the avoidance of  the 
immunosuppressive effects of  cytokines such as TGF-β at the tumor site (36). Nevertheless, as with any 
vascular-targeting approach, there is the possibility that a viable rim of  tumor cells will survive, supported 
by vasculature present in surrounding healthy tissue. Thus, combining CARs that target the vasculature 
with approaches that target the malignant cells directly is likely to be most effective. Proof  of  principle has 
Staining of tumor tissue from mock-treated animals is included as a control. C–E show data from immunofluorescent imaging of CAR- and mock-treat-
ed tumor tissue, with representative images of staining plus a scatterplot of results from individual mice. (C) Data on vascular density (green, MECA32 
endothelial marker; blue, DAPI). (D) CLEC14A expression in vessels (green, MECA32; red, CLEC14A). (E) Proportion of apoptotic vessels (green, cleaved 
caspase-3; red, MECA32; blue, DAPI). All scatterplots show mean ± SEM. All P values shown were calculated using a 2-tailed Mann-Whitney U test (except 
where indicated in A, where the 3 test groups were compared using a Kruskal-Wallis test).
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already been reported in a mouse tumor model that demonstrated a synergistic effect when CAR T cells 
targeting VEGFR2 were combined with CAR T cells targeting an antigen on the malignant cells (37). In 
this case, destroying the tumor vasculature may result in selection of  “normal” vessels that more effectively 
support entry of  tumor antigen–specific T cells into malignant tissue. CAR T cell–mediated targeting of  
tumor vasculature could be combined with chemotherapy, since the selected normal vessels could increase 
drug delivery to the tumor and the CAR T cells could eliminate poorly perfused regions of  tumor that are 
inaccessible or resistant to chemotherapeutic agents. Selected normal vessels will also increase oxygenation 
of  tumor tissue, which is important for effective radiotherapy. Indeed many studies have shown that other 
vascular disruption agents can be combined with chemotherapy or radiotherapy, leading to a synergistic 
antitumor effect (reviewed in ref. 38). If  vascular disruption leads to areas of  hypoxia, this might inhibit 
antitumor immunity and increase invasiveness of  malignant cells. In this case, combining CAR therapy 
with hypoxia-selective bioreductive drugs may also be beneficial (39).
CAR T cells targeting the vasculature will disrupt the tumor microenvironment that could lead to 
release of  tumor antigens. These T cells will also produce cytokines that may recruit other components of  
the immune system. In this way, CAR T cells targeting the tumor vasculature may promote epitope spread-
ing where the host subsequently mounts an immune response to additional tumor-associated antigens (40). 
This could enhance antitumor efficacy by inducing direct targeting of  the malignant cells, especially if  
combined with immune checkpoint inhibitors such as anti–PD-1 antibodies that can activate therapeutic 
host antitumor immunity and may prevent PD-1–mediated inactivation of  the CAR T cells (41).
Figure 7. Antitumor responses in PDAC mice. (A) CLEC14A expression in PDAC tumor tissue (green, MECA32 endothelial marker; red, CLEC14A). FVB/n 
mice were injected into the pancreas with PDAC tumor cells and then conditioned 1 week later with cyclophosphamide. The following day, mice were 
infused with CAR5.28z-expressing mouse T cells (n = 7) or mock-transduced mouse T cells (n = 8). Three weeks later, mice were culled and tumor sizes 
were measured. (B) Results show tumor size for individual mice. (C–E) Representative images of immunofluorescent staining of CAR- and mock-treated 
tumor tissue (red, MECA32 endothelial marker; green, CLEC14A; blue, DAPI; C) to determine vascular density (D) and density of CLEC14A+ vessels (E). All 
scatterplots show data from individual mice, with mean ± SEM. All P values shown were calculated using a 2-tailed Mann-Whitney U test.
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As mentioned above, the potency of  some CAR T cell therapies has led to toxicity in some patients, either 
from cytokine release syndrome or on-target, off-tumor reactivity. We have found expression of  CLEC14A to 
be substantially lower in healthy human tissue, but appropriate measures should be employed to reduce the 
risk of  toxicity in clinical studies. Suicide gene strategies could terminate a toxic response, should it occur, 
and 2 such systems have already proven clinically effective (42, 43), although eliminating the engineered cells 
may also prevent any therapeutic effect. Reducing tumor burden before T cell infusion may reduce the risk of  
cytokine release syndrome, and use of  the IL-6–blocking antibody tocilizumab can be an effective treatment, 
should this syndrome arise (7). To prevent off-target effects with CARs, several strategies have been proposed, 
including use of  combinatorial receptor approaches, where the presence of  2 target antigens is required to 
trigger the T cell, thus permitting selective targeting of  tumor cells, if  they uniquely express both antigens 
(44). Finally, limiting expression of  the CAR either through engineering T cells with RNA leading to transient 
receptor expression (45) or using a drug-inducible on-switch to regulate CAR expression levels (46) should 
allow for greater safety in initial clinical studies.
Given the widespread expression of  CLEC14A in human solid tumors and the non-MHC restricted 
nature of  CAR-expressing T cells, CLEC14A-specific CAR T cells could potentially treat a wide range 
Figure 8. Antitumor responses in the Lewis lung carcinoma mouse 
model. (A) CLEC14A expression in Lewis lung carcinoma tissue (green, 
MECA32 endothelial marker; red, CLEC14A). Scale bar: 50 μm. C57BL/6 
mice were s.c. injected with LLC cells and 4 days later infused with 
mouse T cells expressing CAR3.28z (n = 5), CAR5.28z (n = 4), or mock 
transduced (n = 5). (B and C) Tumor size was measured at the time 
points indicated using bioluminescence (B) or calipers (C). (D) At the end 
of the experiment (day 22 after tumor inoculation), tumors were resect-
ed and weighed. All scatterplots show data from individual mice with 
mean ± SEM. All graphs show mean ± SEM. All P values shown were cal-
culated using a 2-tailed Mann-Whitney U test, except when comparing 
all 3 groups, where a Kruskal-Wallis test was used (as indicated).
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of  cancer patients. Furthermore, given the antitumor efficacy of  these CAR T cells in mouse tumor 
models, clinical studies are warranted to further explore their therapeutic potential, including their use 
in combination therapies.
Methods
Generation of CAR constructs
Hybridomas expressing CLEC14A-specific monoclonal antibodies that cross-react with human and 
mouse forms of  the protein were obtained as described (22). Gene constructs encoding an scFv 
were then isolated from each of  the mouse hybridomas by RT-PCR using degenerate primer sets 
designed to amplify all mouse V-gene families (47). scFv genes were then subcloned into the previ-
ously described CAR vector pMP71.tCD34.2A.CD19.IEVζ (48) as a ClaI/NotI fragment, replacing 
the CD19-specific scFv. This vector was originally constructed using the MP71 retroviral expression 
plasmid (a gift from C. Baum, Hannover Medical School, Hannover, Germany) and coexpressed a 
truncated CD34 marker (49).
Transduction of human and mouse T cells
To generate recombinant retrovirus for transducing human T cells, Phoenix amphotropic packaging 
cells were transfected with an MP71 retroviral vector and pCL ampho (Imgenex) using FuGENE HD 
(Roche) according to the manufacturer’s instructions. Recombinant retrovirus for transducing mouse T 
cells was generated in the same way but using Phoenix ecotropic packaging cells and pCL-Eco. Human 
PBMCs were isolated from heparinized blood by density gradient centrifugation (800g for 30 minutes 
at 20°C) on lymphoprep (Axis Shield). PBMCs were preactivated for 48 hours using anti-CD3 antibody 
(30 ng/mL; OKT3, eBioscience), anti-CD28 antibody (30 ng/mL; 37407, R&D Systems), and IL-2 
(300 U/mL; Chiron) in RPMI1640 (MilliporeSigma) containing 10% FBS (PAA), 2 mM l-glutamine 
(Gibco, Thermo Fisher Scientific), 100 IU/mL penicillin (Gibco, Thermo Fisher Scientific), and 100 
pg/mL streptomycin (Gibco, Thermo Fisher Scientific) (standard medium) plus 1% human AB serum 
(TCS Biosciences). Transduction of  mouse T cells was conducted using mouse splenocytes preactivated 
for 48 hours with concanavalin A (2 μg/mL; MilliporeSigma) and mouse IL-7 (1 ng/mL; eBiosci-
ence) in standard medium. Preactivated human and mouse T cells were subsequently transduced (or 
mock transduced with conditioned supernatant from nontransfected phoenix cells) by spinfection in 
retronectin-coated (Takara) plates according to the manufacturer’s instructions. Human T cells were 
then cultured in standard medium plus 1% human AB serum (TCS Bioscience) with IL-2 (100 U/mL). 
After spinfection, mouse T cells were cultured for 24 hours in standard medium with IL-2 (100 U/mL) 
and were then purified using lymphoprep. Cryopreservation of  mouse T cells was conducted using ice-
cold RPMI1640 containing 50% FBS and 10% dimethyl sulfoxide (MilliporeSigma) and a Mr. Frosty 
cell-freezing device (Nalgene). Cells were then stored over liquid nitrogen. After thawing, viability and 
recovery of  mouse T cells was generally above 50% and 70%, respectively. Where indicated, transduced 
cells were sorted by immunomagnetic selection using anti-CD34 microbeads (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions.
Cell lines and recombinant proteins
Phoenix A and E (National Gene Vector Biorepository, Indiana University, Indianapolis, Indiana, 
USA), CHO, and Lewis lung carcinoma (LLC) (American Type Culture Collection, CRL-1642) cells 
were maintained in DMEM (MilliporeSigma) containing 10% FBS (PAA), 2 mM l-glutamine (Gibco, 
Thermo Fisher Scientific), 100 IU/mL penicillin (Gibco, Thermo Fisher Scientific), and 100 pg/mL 
streptomycin (Gibco). mPDAC (provided by Doug Hanahan and Ksenya Shchors, ISREC, EPFL, Lau-
sanne, Switzerland) were isolated from tumor-bearing p48cre, KrasLSL_G12D, p53R172H/+, and Ink4a/Arffl/+ 
mice and were cultured as previously described (50). CHO cells had been transduced with the pWPI 
vector (Addgene) expressing full-length human CLEC14A (or vector alone). HUVECs were isolated 
and cultured as described (17). Cell lines were screened for mycoplasma using MycoAlert detection kit 
(Lonza). Human and murine CLEC14A proteins (extracellular domains) with a human Fc tag were 
expressed in HEK293T cells and purified on protein A columns as described (22).
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siRNA knockdown of CLEC14A
Transfection with siRNA was performed as described (51) using the following siRNA duplexes: 
D1-GAACAAGACAATTCAGTAA and D2-CAATCAGGGTCGACGAGAA (EuroGentec).
Flow cytometry
HUVECs were trypsinized and stained with CLEC14A-specific mouse monoclonal antibodies described 
above (10 μg/mL) or IgG1 isotype control (Dako) in 5% normal goat serum/PBS. Cells were washed, and 
bound antibodies were detected by incubating with R. phycoerythrin–conjugated (R-PE–conjugated) goat 
anti-mouse antibody (STAR132PE, Serotec). Dead cells were identified using propidium iodide. Human T 
cells were washed with PBS and stained with Live/Dead Fixable Violet Dead Cell Stain Kit (Invitrogen). 
Cells were then washed with flow buffer (0.5% w/v BSA + 2 mM EDTA in PBS; pH 7.2) and stained with 
anti–human CD4 (PE-conjugated, 555347), anti–human CD8 (FITC-conjugated, 555634) (both from BD 
Pharmingen), and anti–human CD34 (PE-Cy5; 343506, BioLegend). Heparinized mouse tail bleeds were 
treated with BD Pharm lyse (Becton Dickinson) before staining T cells as described above but using anti–
mouse CD4–FITC (catalog 553046), –CD8-PE (catalog 553032), and –CD45.1–PE-Cy7 (catalog 560578) 
(BD Pharmingen). Alternatively, CAR expression was detected on human T cells directly by firstly block-
ing cells with human Fc fragment (10 μg/mL) and then incubating them with 10 μg/mL recombinant 
human CLEC14A-Fc fusion protein (or Fc control) followed by sheep anti-CLEC14A polyclonal antibody 
(AF4968, R&D Systems, 10 μg/mL). Finally, cells were stained with FITC-conjugated rabbit anti-sheep 
antibody (818611, Invitrogen). All incubations were conducted for 1 hour on ice. Cells were analyzed using 
a BD LSRII flow cytometer and FlowJo software (Tree Star Inc.).
TNF-α and IL-2 produced by T cells were detected by intracellular cytokine staining. First, T cells were 
incubated with CHO expressing CLEC14A (or vector alone) in standard medium, and after 90 minutes of  
incubation, Brefeldin A (MilliporeSigma) was added at a final concentration of  10 μg/mL. The cells were 
cultured for a further 16.5 hours and then stained with Live/Dead Fixable Violet Dead Cell Stain Kit, 
followed by anti–human CD4–ECD (6604727, Beckman Coulter), anti–human CD8-AmCyan (catalog 
339188), and anti–human CD34–PECy5 (catalog 555823) (both from BD Biosciences). The cells were 
washed in PBS, fixed in 4% paraformaldehyde, treated with PBS containing 0.5% saponin, and stained 
with anti–TNF-α–PECy7 (25-7349-82, eBioscience) or anti–IL-2–PE (559334, BD Pharmingen). Cells 
were then washed in PBS and analyzed using a BD LSRII flow cytometer. Fluorescence minus one controls 
were used to define gates when analyzing data with FlowJo software.
CFSE labeling
T cells were washed twice with PBS and incubated with 2.5 μM CFSE for 10 minutes at 37°C. The labeling 
reaction was quenched by adding RPMI1640 containing 10% FBS. Cells were washed, resuspended in 
standard medium plus 1% human AB serum and IL-2 (10 IU/mL) at 1.5 × 106 cells/mL, and added to 
wells containing HUVECs to give a T cell/HUVEC ratio of  10:1. After 5 days of  incubation at 37oC/5%-
CO2, cells were analyzed by flow cytometry as described above using anti–human CD34 (PE-Cy5).
IFN-γ release assay
Stimulator cells (2.5 × 104/well) were cocultured in triplicate with CD34+ CAR T cells at responder/stim-
ulator ratios indicated. Alternatively 2 × 104 CD34+ CAR T cells were incubated in wells precoated with 
recombinant protein (1 μg/mL). Cells were incubated at 37°C/5% CO2 in 100 μL/well of  RPMI supple-
mented with 10% FBS and IL-2 (25 U/mL). After 18 hours, culture supernatant was tested for secreted 
IFN-γ using an ELISA (Pierce Endogen) according to the manufacturer’s instructions.
Cytotoxicity assays
Chromium release assays have been described previously (52). They were set up at an effector/target ratio 
of  9:1 (1250 targets/well) and harvested after 7.5 hours.
Tissue preparation and immunohistology
Fresh tissues were embedded in OCT (Bio Optica), frozen in dry ice, and stored at –80°C. Tissues were stained 
with the following primary antibodies: purified rat monoclonal anti–panendothelial cell antigen (550563, clone 
Meca32, BD Pharmingen), diluted 1:100; rabbit monoclonal anti–cleaved caspase-3 (asp175, clone 5A1, Cell 
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Signaling Technology), diluted 1:100; rabbit monoclonal anti-CD34 (ab174720, Abcam) diluted 1:50; and sheep 
polyclonal anti-CLEC14A (AF4968, R&D Systems, using a batch that cross-reacted with mouse CLEC14A) 
diluted 1:50. Tissues were incubated with primary antibodies overnight at 4°C. After washing, samples were 
incubated for 1 hour at room temperature with the following secondary antibodies: anti–rat–Alexa Fluor 488 
(A21208) or –Alexa Fluor 350 (A21093); anti–rabbit–Alexa Fluor 488 (A21206) or –Alexa Fluor 555 (A31572); 
and anti–sheep–Alexa Fluor 488 (A11015) (Thermo Fisher Scientific). Samples were then counterstained with 
DAPI Nucleic Acid Stain (Invitrogen). To detect CAR-transduced T cells, tissues were stained overnight at 4°C 
with rabbit monoclonal anti-CD34 (ab174720, Abcam; diluted 1:50 in PBS) and then washed and incubated for 
1 hour at room temperature with anti–rabbit–Alexa Fluor 555 (A21429, Invitrogen) and counterstained with 
DAPI. Tissue from Rip-Tag2 and PDAC mice were analyzed using a Leica TCS SP2 AOBS confocal laser scan-
ning microscope (Leica Microsystems). Acquisitions were performed with the same settings on multiple tissue 
sections and included negative controls for determination of background staining, which was negligible. Vessel 
density was quantified using ImageJ (NIH) software as the area occupied by Meca32+ structures compared with 
the total tissue area. For each animal, the total vessel area of at least 4 field/images was quantified. To analyze 
CLEC14A or cleaved caspase-3 expression, we identified vascular regions in the tissue from Meca32 staining and 
then determined the percentage of this area that was also positively stained for CLEC14A or cleaved caspase-3. 
All other tissues were analyzed using an Axiovert 100M laser scanning confocal microscope (Carl Zeiss).
Tissue sections from Clec14a-knockin mice (see below) were dewaxed in xylene and isopropanol. 
Endogenous peroxidase activity was blocked by 5 minutes of  incubation in a 3% hydrogen peroxide, 90% 
methanol solution. High pH antigen unmasking solution (Vector Laboratories) was heated in an 850W 
microwave oven for 5 minutes; the tissue sections were placed into the solution and heated for a further 15 
minutes before being left to cool for 10 minutes. Nonspecific antibody interactions were then blocked by 
30 minutes of  incubation with 10% horse serum in PBS. Tissues were then stained for human CLEC14A 
using a batch of  polyclonal primary antibody AF4968 (1.7 μg/mL; R&D Systems) that did not cross-react 
with mouse CLEC14A, or concentration-matched isotype control (5-001-A; R&D Systems), for 1 hour at 
23°C, followed by anti–sheep HRP (dilution 1:100; HAF016; R&D Systems) for 1 hour at 23°C. Immuno-
histochemical staining was developed using an ImmPACT NovaRED Peroxidase substrate kit (Vector Lab-
oratories), incubating at 23°C for 3 minutes. Tissues were then counterstained with hematoxylin. Images 
were acquired using a Zeiss Axioskop 40 microscope.
In vivo experiments
Mice were housed in individually ventilated containers with a 12-hour day/night light cycle at temperatures 
of  21°C ± 2°C and relative humidity of  55% ± 5%. All mice were allowed free access to water and a mainte-
nance diet (Eurodent diet, 14%). All cages contained wood shavings, bedding material, and a plastic house.
Exploratory safety testing. Six- to 8-week-old C57BL/6J mice (Charles River Laboratories) received non-
myeloablative (4 Gy) TBI. Eighteen hours later, each mouse received 2 × 107 CAR- or mock-transduced T 
cell preparations from CD45.1+ congenic BoyJ mice (Charles River Laboratories) by tail vein injection. Mice 
were monitored for signs of  toxicity, and immune monitoring was conducted by flow cytometric analysis of  
weekly tail bleeds. Mice were culled 45 days later, and major organs were removed for histological analysis.
Human Clec14a-knockin mouse. C57BL/6J mice were engineered by Jackson Laboratories to express 
the human rather than mouse version of  the extracellular domain of  CLEC14A protein. A chimeric 
gene construct that encoded the human signal peptide and extracellular domain of  CLEC14A and the 
mouse transmembrane and intracellular domains were inserted into the start codon of  the endogenous 
mouse Clec14a gene, putting the latter out of  frame and preventing transcription of  the WT mouse Cle-
c14a gene. Gene insertion was conducted using CRISPR/Cas9-based gene editing with the following 
guide RNAs: CLEC14A_up_sgRNA1, 5′-CAGCTGCATGTTGAGTCTCC-3′; CLEC14A_up_sgR-
NA2, 5′-CATGTTGAGTCTCCAGGATG-3′; CLEC14A_down_sgRNA1, 5′-GGCAAGCGCTGG-
CCTCATCC-3′; and CLEC14A_down_sgRNA2, 5′-AGGAGGCACAGGGCAAGCGC-3′.
The identity of  the knockin mouse was confirmed by PCR genotyping.
Wound healing assay. C57BL/6J mice were injected s.c. into the flank with 1 × 106 LLC cells. Three days 
later, they were irradiated (4 Gy) and injected i.v. with 10 × 106 CAR T cells (with 75% of  cells expressing 
the CAR) or mock T cells (n = 7 mice per group). One day after T cell injection, skin wounds were admin-
istered with a 4 mm punch biopsy needle to the opposite flank of  the mouse. Wound healing was assessed 
for the following 8 days, measuring the wound area with ImageJ from photographs taken alongside a scale.
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Rip-Tag2 transgenic mouse tumor model. Generation of  RIP-Tag2 mice as a model of  pancreatic islet 
cell carcinogenesis has been previously reported (53). Male RIP-Tag2 mice (provided by Doug Hanahan, 
ISREC, EPFL, Lausanne, Switzerland) were maintained on a C57BL/6J background (The Jackson Lab-
oratory). From 12 weeks of  age, all RIP-Tag2 mice received 50% sugar food (Harlan Teklad) to relieve 
hypoglycemia induced by the insulin-secreting tumors. At 12 weeks of  age, mice received 4 Gy TBI using 
6 MV x-ray produced by Tomotherapy Hi Art Unit (Accuray Inc.). Before treatment, a high-resolution CT 
scan virtual simulation (Toshiba Aquilion LB) was performed in order to define the treatment plan. Mega-
voltage CT verified the correct positioning of  the mouse; then, TomoDirect Intensity Modulated Radiation 
Therapy was applied, allowing the delivery of  95% of  the prescribed dose to the animal. The following day, 
cryopreserved CAR- and mock-transduced T cell preparations were thawed and washed, and 15 × 106 T 
cells/mouse were delivered systemically by tail vein injection. Note the CAR T cell preparation contained 
2.4 × 106 T cells expressing CAR5.28z. Total tumor burden in culled CAR T cell–treated mice was quanti-
fied at 16 weeks of  age using calipers to measure individually excised macroscopic tumors (>1 mm3) using 
the formula volume = a × b2 × 0.52, where a and b represent the longer and shorter diameter of  the tumor, 
respectively. Volumes of  all tumors from each mouse were added to give the total tumor burden per animal. 
There are no age-matched control comparisons for the 16-week CAR-treated mice, since untreated RIP-
Tag2 mice do not survive to 16 weeks; thus, the comparison was made to 14-week-old mock-treated mice.
PDAC model. The orthotopic mouse model of  pancreatic ductal adenocarcinoma (mPDAC) has been 
described previously (50). Briefly, FVB/n syngeneic mice (Charles River Laboratories) were injected 
orthotopically in the pancreas with mPDAC cells (5 × 103 cells/mouse in 50 μL of  PBS). One week later, 
mice were conditioned by i.p. injection of  cyclophosphamide (200 mg/kg). Twenty-four hours later, cryo-
preserved CAR-transduced T cells (of  which 70% expressed CAR5.28z) and mock-transduced T cells were 
thawed and washed, and 20 × 106 T cells/mouse were injected i.v. Three weeks after T cell infusion, mice 
were culled, and the pancreas was removed. Total tumor burden was quantified as described above.
LLC mouse model. Six- to 8-week-old female C57BL/6J mice (Charles River Laboratories) were inocu-
lated s.c. on the flank with 1 × 106 LLC cells. Three days later, mice received 4 Gy TBI, and 18 hours after 
that, each mouse received 2 × 107 CAR or mock T cell preparations from CD45.1+ congenic BoyJ mice by 
tail vein injection. CAR T cell preparations expressed either CAR3.28z or CAR5.28z with 11% and 7% of  
cells expressing the CAR, respectively. Tumor growth was measured with calipers, with bioluminescence 
imaging (IVIS Spectrum, Caliper Life Sciences), and by weight (after resection).
Statistics
All statistical analyses were performed using GraphPad Prism software. Statistical tests used in this study 
were as follows: Wilcoxon matched-pairs signed rank test, unpaired 2-tailed t test, 2-tailed Mann-Whitney 
U test, and Kruskal-Wallis test. P < 0.05 was considered significant.
Study approval
Studies with human donors were approved by the National Research Ethics Service Committee West Mid-
lands, and all donors gave written informed consent before inclusion in the study. All procedures with 
Rip-Tag2 and mPDAC mouse models were approved by the Ethics Committee of  the University of  Turin 
and by the Italian Ministry of  Health, in compliance with international laws and policies. All other mouse 
studies were performed under UK Home Office authorization.
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